GeneDx Holdings Statistics
Total Valuation
GeneDx Holdings has a market cap or net worth of $3.06 billion. The enterprise value is $3.03 billion.
Important Dates
The last earnings date was Tuesday, February 18, 2025.
| Earnings Date | Feb 18, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
GeneDx Holdings has 27.78 million shares outstanding. The number of shares has increased by 10.61% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 27.78M |
| Shares Change (YoY) | +10.61% |
| Shares Change (QoQ) | +2.54% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 17.90M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 116.49 |
| PS Ratio | 10.01 |
| Forward PS | n/a |
| PB Ratio | 12.47 |
| P/TBV Ratio | 35.29 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 9.93 |
| EV / EBITDA | 6,164.28 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.61, with a Debt / Equity ratio of 0.47.
| Current Ratio | 3.61 |
| Quick Ratio | 3.26 |
| Debt / Equity | 0.47 |
| Debt / EBITDA | 15.08 |
| Debt / FCF | n/a |
| Interest Coverage | -7.08 |
Financial Efficiency
Return on equity (ROE) is -22.10% and return on invested capital (ROIC) is -3.78%.
| Return on Equity (ROE) | -22.10% |
| Return on Assets (ROA) | -3.20% |
| Return on Invested Capital (ROIC) | -3.78% |
| Return on Capital Employed (ROCE) | -5.89% |
| Revenue Per Employee | $305,450 |
| Profits Per Employee | -$52,286 |
| Employee Count | 1,000 |
| Asset Turnover | 0.73 |
| Inventory Turnover | 11.43 |
Taxes
| Income Tax | -343,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +991.70% in the last 52 weeks. The beta is 2.08, so GeneDx Holdings's price volatility has been higher than the market average.
| Beta (5Y) | 2.08 |
| 52-Week Price Change | +991.70% |
| 50-Day Moving Average | 0.19 |
| 200-Day Moving Average | 0.11 |
| Relative Strength Index (RSI) | 56.45 |
| Average Volume (20 Days) | 33,978 |
Short Selling Information
The latest short interest is 6,282, so 0.02% of the outstanding shares have been sold short.
| Short Interest | 6,282 |
| Short Previous Month | 7,753 |
| Short % of Shares Out | 0.02% |
| Short % of Float | 0.04% |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, GeneDx Holdings had revenue of $305.45 million and -$52.29 million in losses. Loss per share was -$1.94.
| Revenue | 305.45M |
| Gross Profit | 194.45M |
| Operating Income | -21.46M |
| Pretax Income | n/a |
| Net Income | -52.29M |
| EBITDA | 492,000 |
| EBIT | -21.46M |
| Loss Per Share | -$1.94 |
Full Income StatementBalance Sheet
The company has $141.19 million in cash and $116.17 million in debt, giving a net cash position of $25.02 million or $0.90 per share.
| Cash & Cash Equivalents | 141.19M |
| Total Debt | 116.17M |
| Net Cash | 25.02M |
| Net Cash Per Share | $0.90 |
| Equity (Book Value) | 245.25M |
| Book Value Per Share | 8.83 |
| Working Capital | 143.15M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$28.50 million and capital expenditures -$5.49 million, giving a free cash flow of -$33.99 million.
| Operating Cash Flow | -28.50M |
| Capital Expenditures | -5.49M |
| Free Cash Flow | -33.99M |
| FCF Per Share | -$1.22 |
Full Cash Flow StatementMargins
Gross margin is 63.66%, with operating and profit margins of -7.03% and -17.12%.
| Gross Margin | 63.66% |
| Operating Margin | -7.03% |
| Pretax Margin | -17.23% |
| Profit Margin | -17.12% |
| EBITDA Margin | 0.16% |
| EBIT Margin | -7.03% |
| FCF Margin | n/a |